IACC Workshop on Under-Recognized Co-Occurring Conditions in ASD - September 23, 2014

• View by Meeting Topic

Technical difficulties were experienced with the conference call this morning. The issues have been resolved. We apologize for any inconvenience.

Topic	Topic Description
Date:	Tuesday, September 23, 2014
Time:	9:00 a.m. to 5:00 p.m. Eastern
Place:	National Institutes of Health John Edward Porter Neuroscience Research Center 35 Convent Drive, Building 35, Room 620 Bethesda, Maryland 20892 Map and Directions
Webcast:	http://videocast.nih.gov
Agenda:	The workshop will focus on a range of co-occurring health conditions in individuals with ASD that are under-recognized in clinical and services settings, as well as how to best support research, increased community/provider awareness, and other activities to improve the quality of life of those with ASD who are affected by these conditions.
Cost:	The meeting is free and open to the public.
Registration:	On-site registration is from 8:30 a.m. to 9:00 a.m. Pre-registration is recommended to expedite check-in. Seating in the meeting room is limited to room capacity and on a first come, first served basis. Online pre-registration will close at 5:00 p.m. Eastern the day before the meeting. After that time, you will need to register onsite the day of the meeting.
Access:	Medical Center Metro Station (Red Line). On-site parking is available for a fee, but very limited. Vehicles entering the NIH campus are subject to security inspections, and visitors must present photo identification for NIH campus access.
Conference Call Access:	Dial: (888) 469-0570 Access code: 7134439
Materials:	Meeting materials
Deadlines:	Notification of intent to present oral comments: Monday, September 8, 2014 by 5:00 p.m. Eastern Submission of written/electronic statement for oral comments: Wednesday, September 10, 2014 by 5:00 p.m. Eastern Final Deadline for Submission of written comments: Wednesday, September 10, 2014 by 5:00 p.m. Eastern Please read the IACC Public Comment guidelines.
Contact Person:	Ms. Lina Perez Office of Autism Research Coordination National Institute of Mental Health, NIH 6001 Executive Boulevard, NSC, Room 6182A Rockville, Maryland 20852 Phone: (301) 443-6040 E-mail: IACCPublicInquiries@mail.nih.gov
Public Comment:	Any member of the public age 18 and above interested in presenting oral comments to the Committee must notify the Contact Person listed on this notice by 5:00 p.m. Eastern on Monday, September 8, 2014, with their request to present oral comments at the meeting. Interested individuals and representatives of organizations must submit a written/electronic copy of the oral presentation/statement including a brief description of the organization represented by 5:00 p.m. Eastern on Wednesday, September 10, 2014. Statements submitted will become a part of the public record. Only one representative of an organization or family will be allowed to present oral comments on behalf of that organization or family, and presentations will be limited to 2-3 minutes per speaker, depending on number of speakers to be accommodated within the allotted time. Speakers will be assigned a time to speak in the order of the date and time when their request to speak is received, along with the required submission of the written/electronic statement by the specified deadline. In the case that there are more oral comments requested than can be accommodated in the time allotted, a waiting list will be maintained, and if an oral commenter is unable to meet the deadline for the submission of the accompanying written statement, his/her spot may be ceded to the next person on the waiting list. Any individuals who request oral comments but cannot be accommodated due to time limitations will be welcome to provide written public comments. In addition, any interested person age 18 and above may submit written comments to the IACC prior to the meeting by sending the comments to the Contact Person listed on this notice by 5:00 p.m. Eastern on Wednesday, September 10, 2014. The comments should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. NIMH anticipates written public comments received by 5:00 p.m. Eastern, Wednesday, September 10, 2014 will be presented to the Committee prior to the meeting for the Committee's consideration. Any written comments received after the September 10, 2014 deadline (between September 10-22, 2014) will be provided to the Committee either before or after the meeting, depending on the volume of comments received and the time required to process them in accordance with privacy regulations and other applicable Federal policies. All written public comments and oral public comment statements received by the deadlines for both oral and written public comments will be provided to the IACC for their consideration and will become part of the public record. Privacy: Public comments provided to or prepared on behalf of the IACC become a part of the public record of the committee, so information that is private, confidential, copyrighted or proprietary should not be included, other than contact information to enable OARC or the IACC to contact a commenter if necessary. By voluntarily providing comments to the IACC, the commenter is consenting to the use and consideration of these comments by the committee and relevant federal agencies. Public comments received are prepared by OARC for the committee in accordance with the FACA, the Freedom of Information Act (FOIA), the Privacy Act, and other applicable laws, regulations and policies. With regard to written public comments, unless a specific request is made in writing to IACCPublicInquiries@mail.nih.gov to withhold the commenter's name, city, state, and affiliation, that information will remain in the comment. Other personally identifiable information, such as: street addresses; personal e-mail addresses; personal phone numbers; names of minors, dependent adults, and private third party individuals; photographs of individuals or photos depicting sensitive personal information; medical and educational records; and other sensitive personal records, will be redacted. In addition, foul, obscene, threatening, violent, derogatory or hate language or photos will be redacted. Please refrain from including such material in submissions. Written statements prepared in conjunction with oral public comments will also be redacted according to the above guidelines. With regard to oral public comments made at public meetings of the IACC, any information that is shared by the commenter during the public comment session, including the commenter's name, city, state, and affiliation, will become a part of the public record and may be included or referenced in meeting proceedings or other committee records. Due to the public nature of IACC public comments, including the posting of materials related to the IACC on a government website, and the need to protect the privacy of minors, only individuals age 18 and above will be permitted to provide public comments to the IACC. In the future, IACC public comments redacted per the above guidelines will be made available to the public on the IACC website. In addition, information pertaining to public comments may also be included or referenced in other public records of the IACC, such as meeting minutes, transcripts and videos that are made available to the public on the IACC website. Core Values: In the 2009 IACC Strategic Plan, the IACC listed the "Spirit of Collaboration" as one of its core values, stating that, "We will treat others with respect, listen to diverse views with open minds, discuss submitted public comments, and foster discussions where participants can comfortably offer opposing opinions." In keeping with this core value, the IACC and the NIMH Office of Autism Research Coordination (OARC) ask that members of the public who provide public comments or participate in meetings of the IACC also seek to treat others with respect and consideration in their communications and actions, even when discussing issues of genuine concern or disagreement. Please read the IACC Public Comment guidelines.
Please Note:	Remote Access: This workshop will also be open to the public through a conference call number and live webcast on the Internet. Members of the public who participate using the conference call phone number will be able to listen to the discussion but will not be heard. If you experience any technical problems with the webcast or conference call, please send an e-mail to HelpDeskIACC@gmail.com or by phone at 415-652-8023. Special Accommodations: Individuals who participate in person or by using these electronic services and who need special assistance, such as captioning of the conference call or other reasonable accommodations, should submit a request to the contact person listed on this notice at least 5 days prior to the meeting. Security: In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit. Also as a part of security procedures, attendees should be prepared to present a photo ID at the meeting registration desk during the check-in process. Pre-registration is recommended. Seating will be limited to the room capacity and seats will be on a first come, first served basis, with expedited check-in for those who are pre-registered. Meeting schedule is subject to change.

Back to Top

Time	Event
9:00 a.m.	Welcome and Introductions Thomas Insel, M.D Director, National Institute of Mental Health (NIMH) Chair, IACC Co-Chair, IACC Basic and Translational Research Subcommittee Geraldine Dawson, Ph.D., F.A.P.A., F.A.P.S Professor Departments of Psychiatry and Behavioral Science, Psychology Neuroscience Director, Duke Center for Autism and Brain Development Duke University School of Medicine Duke Institute for Brain Sciences Co-Chair, IACC Basic and Translational Research Subcommittee Susan Daniels, Ph.D. Director, Office of Autism Research Coordination (OARC), NIMH Executive Secretary, IACC
9:15 a.m.	Panel 1: Overview of Co-Occurring Conditions in Children and Adults – What have We Learned about Co-Occurring Conditions from Epidemiological and Clinical Experience? 9:15 Anjali Jain, M.D. Vice President Lewin Group 9:30 a.m. Lisa Croen, Ph.D., M.P.H. Director, Kaiser Permanente Autism Research Program Senior Research Scientist, Division of Research Kaiser Permanente Northern California 9:45 a.m. Isaac Kohane, M.D., Ph.D Lawrence J. Henderson Professor of Pediatrics and Health Sciences and Technology Harvard Medical School Director, Francis A. Countway Library of Medicine Harvard University 10:00 a.m. Daniel L. Coury, M.D. Chief, Section on Developmental and Behavioral Pediatrics Chief, Child Development Center Program Director, Developmental/Behavioral Pediatrics Fellowship, Nationwide Children's Hospital Professor of Pediatrics and Psychiatry, College of Medicine, The Ohio State University
10:15 a.m.	Discussion
10:45 a.m.	Break
11:00 a.m.	Panel 2: Psychiatric Disorders 11:00 a.m. Lawrence Scahill, Ph.D., M.S.N., M.P.H Professor of Psychiatry, School of Medicine Director of Clinical Trials, Marcus Autism Center Emory University 11:15 a.m. Jeffrey Wood, Ph.D Clinical Child Psychologist Associate Professor Division of Child Psychiatry and Human Development and Psychology Graduate School of Education and Information Studies University of California, Los Angeles 11:30 a.m. Evdokia Anagnostou, M.D Senior Clinician Scientist Associate Professor Bloorview Research Institute, University of Toronto Canada Research Chair in Translational therapeutics in ASD University of Toronto
11:45 a.m.	Discussion
12:15 p.m.	Lunch
12:45 p.m.	Public Comment
1:00 p.m.	Discussion of Public Comment
1:15 p.m.	Panel 3: Sleep and Neurological Disorders 1:15 p.m. Beth Malow, M.D., M.S. Professor of Neurology and Pediatrics Department of Neurology and Pediatrics School of Medicine Vanderbilt University 1:30 p.m. Ashura Buckley, M.D. Clinical Investigator National Institute of Mental Health National Institutes of Health 1:45 p.m. Mustafa Sahin, M.D., Ph.D. Director of Translational Neuroscience Center, Boston Children's Hospital Associate Professor of Neurology Harvard Medical School Harvard University
2:00 p.m.	Discussion
2:30 p.m.	Break
2:45 p.m.	Panel 4: Metabolic and Immune Disorders 2:45 p.m. Carlos Pardo-Villamizar, M.D Associate Professor of Neurology and Pathology School of Medicine Johns Hopkins University 3:00 p.m. Judy Van de Water, Ph.D. Professor Department of Internal Medicine, School of Medicine Director, Center for Children's Environmental Health Co-Director, Intellectual and Developmental Disabilities Research Center (IDDRC), MIND Institute University of California, Davis 3:15 p.m. Robert K. Naviaux, M.D., Ph.D., M.S. Professor Departments of Medicine, Pediatrics, and Pathology Co-Director, Mitochondrial and Metabolic Disease Center Director of Metabolomics Core, Veterans Affairs Center for Excellence in Stress and Mental Health School of Medicine University of California, San Diego
3:30 p.m.	Discussion
4:00 p.m.	Group Discussion & Wrap-up
5:00 p.m.	Adjournment

Back to Top

Evdokia Anagnostou, M.D.

Dr. Anagnostou is a child neurologist and clinician scientist at Bloorview Research Institute. Her research focuses on the psychopharmacology and neuroimaging of autism. Dr. Anagnostou is Principal Investigator or Co-Investigator on multiple clinical trials in autism and has had extensive funding in both pharmacology and neuroimaging. She also leads the Ontario Brain Institute-funded POND grant that embeds a clinical trial network in a biomarkers core for autism spectrum disorder (ASD), ADHD, ID, and OCD. Dr. Anagnostou's research at Holland Bloorview Kids Rehabilitation Hospital focuses on the development of clinical trials to test novel compounds for the treatment of autism and related disorders. In collaboration with imaging researchers at the Hospital for Sick Children (SickKids), she is also studying the developmental trajectory of abnormalities in the frontostriatal circuitry and social cognition circuitry in autism and is exploring the mechanisms of treatment response and side effects generation using fMRI, MR spectroscopy, and DTI techniques.

Ashura Buckley, M.D.

Dr. Buckley is a child neurologist, sleep specialist, and clinical investigator at the National Institute of Mental Health (NIMH). She received her undergraduate degree from Harvard University (1994) and her medical degree from the State University of New York at Stony Brook (2000) and completed her training in child neurology at Massachusetts General Hospital (2005). Dr. Buckley was a fellow at the Pediatrics and Developmental Neuroscience Branch at NIMH from 2006 to 2009, where she became an integral part of NIH's intramural autism phenotyping efforts. From 2009 to 2011 she was a Ruth L. Kirschstein National Research Service Award Fellow pursuing additional certification in sleep medicine and is now a diplomate of the American Board of Psychiatry and Neurology in both sleep medicine and psychiatry and neurology, with special qualifications in child neurology. Dr. Buckley is particularly interested in the role of sleep in neurodevelopmental/neuropsychiatric disorders, with a focus on abnormal sleep neurophysiology in children with severe forms of autism, obsessive compulsive disorder, schizophrenia, and other serious mental illnesses. The goal of her research is to elucidate underlying aberrant neurotransmission in these disorders that might offer potential therapeutic targets. Dr. Buckley also works closely with the American Academy of Neurology (AAN) and is the lead author of AAN's forthcoming "Treatment Guidelines for Autism" in 2015.

Daniel Coury, M.D.

Dr. Coury is Chief of the Section on Developmental and Behavioral Pediatrics at Nationwide Children's Hospital and a Professor of Pediatrics and Psychiatry at The Ohio State University College of Medicine. He received his medical degree from the University of Tennessee Center for Health Sciences, followed by an internship and residency in pediatrics there. Dr. Coury then was a fellow in ambulatory pediatrics at Brown University. His research interests include developmental and behavioral pediatrics, medical education, attention deficit hyperactivity disorder, and autism. Dr. Coury is also Medical Director of the Autism Treatment Network of Autism Speaks and of the Autism Intervention Research Network on Physical Health, which is supported by the Health Resources and Services Administration, U.S. Department of Health and Human Services (DHHS).

Lisa Croen, Ph.D., M.P.H.

Dr. Croen is a Senior Research Scientist at the Division of Research, Kaiser Permanente Northern California (KPNC), and Director of the Kaiser Permanente Autism Research Program. Her research interests include the epidemiology of autism and other neurodevelopmental disorders, environmental exposures and gene-environment interactions, and adverse perinatal outcomes. Dr. Croen is Principal Investigator (PI) of the NIH-funded Early Markers for Autism study and site PI of two large federally funded autism studies: the Study to Explore Early Development (SEED) and the Early Autism Risk Longitudinal Investigation (EARLI). She is also Co-Investigator of the California Autism Twins Study (CATS). In collaboration with clinical colleagues, Dr. Croen is conducting a mixed-methods study to evaluate autism treatments at KPNC and is investigating health status and health care utilization of adults with autism. She received her master's degree in public health and her doctorate in epidemiology from the University of California, Berkeley.

Anjali Jain, M.D.

Dr. Jain is a general pediatrician and Vice President at the Lewin Group, a health and human services research and policy group in Falls Church, Virginia. She is Project Director of the NIH-funded "Study of Health Outcomes in Children with Autism and their Families" and of projects funded by the Agency for Healthcare Research and Quality, DHHS, to improve health care transitions for individuals with sickle cell disease using health information technology and to evaluate Stage 3 Meaningful Use objectives. Overall, Dr. Jain's work in research and policy has focused on children's health, comparative effectiveness research, and public health more generally, particularly obesity prevention among low-income and minority populations. She is a fellow of the American Academy of Pediatrics and of The Obesity Society and served as Chair of the Health Care Subcommittee of the State of Maryland Committee on Childhood Obesity. Prior to her work at Lewin, Dr. Jain was an Assistant Professor in Pediatrics and Health Policy at Children's National Medical Center and The George Washington University. Her 15 years of clinical experience is primarily among underserved children and families. Dr. Jain received a B.S. degree with honors in chemical engineering and an M.D. degree from the University of Virginia. She was a resident and Chief Resident in Pediatrics at the University of Chicago and went on to be a Robert Wood Johnson Clinical Scholar at Yale University and Assistant Professor of Pediatrics at the University of Chicago. Dr. Jain also worked as a physician editor for the British Medical Journal Publishing Group and as a research fellow at the University College London in the United Kingdom and is currently an Associate Editor for "Academic Pediatrics."

Isaac Kohane, M.D., Ph.D.

Dr. Kohane is Co-Director of the Center for Biomedical Informatics at Harvard Medical School (HMS). He is also Director of Harvard University's Francis A. Countway Library of Medicine, Director of the Boston Children's Hospital (BCH) Informatics Program, and Henderson Professor of Pediatrics and Health Sciences and Technology at HMS. Dr. Kohane is a founder of the Center for Outcome and Policy Research at the Dana-Farber Cancer Institute and is Founder and Associate Director of the Center for Genetic Epidemiology at HMS. He is a fellow of the American College of Medical Informatics and of the Society for Pediatric Research, a member of the Institute of Medicine, and a member of the American Society for Clinical Investigation. Dr. Kohane leads multiple collaborations at HMS and its hospital affiliates in the use of genomics and computer science to study cancer and the development of the brain (with emphasis on autism). He has developed several computer systems to allow multiple hospital systems to be used as "living laboratories" to study the genetic basis of disease while preserving patient privacy. Dr. Kohane's research builds on his doctoral work in computer science on decision support and subsequent research in machine learning applied to biomedicine. Dr. Kohane leads several NIH-funded efforts to translate genomic research into clinical practice and continues his own practice in pediatric endocrinology at BCH.

Beth Malow, M.D., M.S.

Dr. Malow is a tenured Professor of Neurology and Pediatrics, holds the Michael Burry Chair in Cognitive Childhood Development, and directs the Vanderbilt Sleep Division at Vanderbilt University. The focus of her research is the impact of sleep on neurological conditions, with an emphasis on developmental disorders, including autism. Dr. Malow is Director of Vanderbilt's Autism Speaks Autism Treatment Network (ATN) and co-chairs ATN's sleep workgroup. She is also Principal Investigator of the Vanderbilt NeuroNEXT site (NIH Network of Excellence in Neuroscience Clinical Trials). Dr. Malow received her B.S. degree from Northwestern University in 1984 and her M.D. degree from the Feinberg School of Medicine at Northwestern University. Her residency in the Harvard Longwood Neurology Training Program from 1988 to 1991 was followed by a fellowship in epilepsy, EEG, and sleep at NIH from 1991 to 1994. Dr. Malow received K08 and K02 awards while she was on the faculty at the University of Michigan, where she completed an M.S. degree in clinical research design and statistical analysis in 1997. Dr. Malow is board certified in sleep medicine.

Robert K. Naviaux, M.D., Ph.D., M.S.

Dr. Naviaux is a Professor of Medicine, Pediatrics, Pathology, and Genetics at the University of California, San Diego (UCSD). He is the Founder and Co-Director of the Mitochondrial and Metabolic Disease Center and discovered the cause of the classic mitochondrial disease, Alpers syndrome. Dr. Naviaux's research experience spans 35 years and embraces the fields of human genetics, autism, virology, cancer, metabolism, and mitochondrial medicine. He received his undergraduate degree from the University of California, Davis, was an undergraduate research intern in tumor immunology at NIH, and studied biochemistry at the Georg-August University in Göttingen, Germany. Dr. Naviaux was trained as a medical scientist at the Indiana University School of Medicine, where he received both M.D. and Ph.D. degrees, graduating with highest distinction. In 1990 he was named 1 of 10 National Medical Residents of the Year for clinical excellence by NIH. Dr. Naviaux completed his advanced training in virology and molecular biology at the Salk Institute for Biological Studies in La Jolla, California, where he conducted research in cancer gene therapy and basic retrovirus biology in the laboratory of Dr. Inder M. Verma. He is the inventor of the popular pCL retroviral gene transfer vectors. Dr. Naviaux trained in biochemical genetics with Dr. William Nyhan and neurometabolic disease with Dr. Richard Haas at UCSD. In 2011 he received one of three Suzanne and Bob Wright Trailblazer Awards from Autism Speaks for his research in autism. This work led to the discovery of the role of purinergic signaling and cell danger response in ASD.

Carlos Pardo-Villamizar, M.D.

Dr. Pardo is Associate Professor of Neurology and Pathology, a neurologist and neuropathologist, and Principal Investigator of the Neuroimmunopathology Laboratory at the John Hopkins University (JHU) School of Medicine. He is also a neurologist at the JHU Multiple Sclerosis Center and a member of the HIV Neurosciences Research Group. Dr. Pardo's clinical research interest and laboratory work focus on studies of the immunopathologic and molecular mechanisms associated with neuroimmune disorders such as neuroAIDS, multiple sclerosis, transverse myelitis, epilepsy, and autism; the roles of cytokines and chemokines in pathogenic mechanisms of neurological disorders; studies of biomarkers of neuroimmunologic disease in cerebrospinal fluid (CSF) and blood; and animal models of neuroimmunologic disorders. His interest in autism centers on studies of potential immunological factors that may influence pathogenesis, biomarkers in CSF and blood, the role of neuroimmune factors in behavior, and neurological manifestations associated with autism. Along with scientists at the Intramural Autism Research Program at NIMH, Dr. Pardo focuses on clinical and laboratory studies to characterize the role of immunological factors in a large cohort of patients with autism.

Mustafa Sahin, M.D., Ph.D.

Dr. Sahin received his B.S. degree from Brown University and his M.D. and Ph.D. degrees from the Yale University School of Medicine. He completed a pediatrics residency at the Children's Hospital of Philadelphia, a child neurology residency at Boston Children's Hospital (BCH), and postdoctoral research training in developmental neurobiology at BCH. Dr. Sahin established and directs the Multidisciplinary Tuberous Sclerosis Program at BCH. He has received numerous awards, including a Spinal Muscular Atrophy Foundation/AAN Young Investigator Award, the 2005 Young Investigator Award from the Child Neurology Society, and a 2009 John Merck Scholars Program Award. Research in the Sahin laboratory is directed at understanding the cellular mechanisms of axon guidance and their relationship to neurological dysfunction. His research centers on tuberous sclerosis complex (TSC) and spinal muscular atrophy—two neurological disorders whose genetic bases are well understood but whose cell biologies remain unknown. Dr. Sahin's lab has generated four lines of evidence showing that the TSC/mTOR pathway plays crucial roles in axon specification, guidance, myelination, and regeneration. These experiments support the notion that neurological defects in TSC-deficient mice can be blocked by postnatal mTORC1 inhibition and have led to the design of a clinical trial directed by Dr. Sahin in patients with TSC to investigate the effect of an mTORC1 inhibitor on neurocognition.

Lawrence Scahill, Ph.D., M.S.N., M.P.H.

Dr. Scahill is Professor of Pediatrics at Emory University and Director of Clinical Trials at the Marcus Autism Center in Atlanta. He has been a Principal Investigator in the Research Units on Pediatric Psychopharmacology (RUPP) Autism Network since 1997. The RUPP Network has had a substantial impact on practice through the completion of several multisite trials and cultivation of outcome measures for use in clinical trials in ASD. With funding from NIMH, Dr. Scahill is leading an effort to develop two instruments for measuring anxiety in children with ASD. He has written and published more than 200 journal articles and numerous book chapters.

Judy Van de Water, Ph.D.

Dr. Van de Water is a well-known immunologist whose primary interests for more than 20 years have included autoimmunity, immunopathology, and molecular and cell biology. Her laboratory research programs include the identification of the various mechanisms associated with autoimmune and other immune-mediated disorders. This includes the biological aspects of ASD, including immune dysfunction and autoantibody production. In addition, Dr. Van de Water's current work involves the identification of maternal antibodies to fetal brain proteins found in some mothers of children with autism. She is Director of the National Institute of Environmental Health Sciences' Center for Children's Environmental Health and Principal Investigator of the Center's Project 3. Dr. Van de Water is also Co-Director of the newly awarded National Institute of Child Health and Human Development's Intellectual and Developmental Disabilities Research Center at the University of California, Davis, MIND Institute.

Jeffrey Wood, Ph.D.

Dr. Wood is a clinical child psychologist with a joint appointment as Associate Professor in the Division of Human Development and Psychology and the Division of Child Psychiatry at University of California, Los Angeles (UCLA). He is also a faculty member of the UCLA Center for Autism Research and Treatment. Dr. Wood received a Ph.D. degree in clinical psychology from UCLA, specializing in clinical trials of cognitive behavioral therapy for childhood anxiety disorders and obsessive-compulsive disorder. He has received several awards from NIMH, the American Educational Research Association, and UCLA and has obtained multiple grants from NIMH, the Cure Autism Now Foundation, Autism Speaks, and the Organization for Autism Research to study cognitive behavioral interventions for school-age children with autism. Dr. Wood's work has been published in scholarly journals such as the "Journal of Child Psychology and Psychiatry," "Developmental Psychology," and "Journal of Autism and Developmental Disorders." He is Principal Investigator of several studies of cognitive behavioral therapy for children and adolescents with ASD, with treatments focusing on core autism symptoms as well as anxiety.

Back to Top

• Oral Public Comments (PDF – 103 KB)
• Written Public Comments (PDF – 431 KB)

Back to Top

• Discussion Questions for IACC Workshop on Under-Recognized Co-Occurring Conditions (PDF – 80 KB)
• Autism Co-Occurring Conditions Guidelines and Publications

Back to Top

• IACC Workshop Full Slide Set (PDF 28 MB)

Presentation	Presenter(s)
Lessons from Epidemiological and Clinical Experience (PDF – 472 KB)	Anjali Jain, M.D., Vice President, Lewin Group
Psychiatric and Medical Conditions Among Adults with ASD (PDF – 1.3 MB)	Lisa Croen, Ph.D., M.P.H., Director, Kaiser Permanente Autism Research Program, Senior Research Scientist, Division of Research, Kaiser Permanente Northern California
Autism and Autisms (PDF – 4 MB)	Isaac Kohane, M.D., Ph.D., Lawrence J. Henderson Professor of Pediatrics and Health Sciences and Technology, Harvard Medical School, Director, Francis A. Countway Library of Medicine, Harvard University
Autism Spectrum Disorder and Co-Occurring Conditions (PDF – 449 KB)	Daniel L. Coury, M.D., Chief, Section on Developmental and Behavioral Pediatrics, Chief, Child Development Center, Program Director, Developmental/Behavioral, Pediatrics Fellowship, Nationwide Children's Hospital, Professor of Pediatrics and Psychiatry, College of Medicine, The Ohio State University
Toward Better Measurement of Anxiety in ASD: Outline (PDF – 202 KB)	Lawrence Scahill, Ph.D., M.S.N., M.P.H., Professor of Psychiatry, School of Medicine, Director of Clinical Trials, Marcus Autism Center, Emory University
Psychiatric Comorbidity in Individuals with ASD (PDF – 203 KB)	Jeffrey Wood, Ph.D., Clinical Child Psychologist, Associate Professor, Division of Child Psychiatry and Human Development and Psychology, Graduate School of Education and Information Studies, University of California, Los Angeles
Psychiatric Comorbidities in ASD (PDF – 683 KB)	Evdokia Anagnostou, M.D., Senior Clinician Scientist, Associate Professor, Bloorview Research Institute, University of Toronto, Canada Research Chair in Translational therapeutics in ASD, University of Toronto
Sleep in Autism (PDF – 770 KB)	Beth Malow, M.D., M.S., Professor of Neurology and Pediatrics, Department of Neurology and Pediatrics, School of Medicine, Vanderbilt University
Epilepsy and ASD (PDF – 451 KB)	Ashura Buckley, M.D., Clinical Investigator, National Institute of Mental Health, National Institutes of Health
Dissecting the Neural Circuitry of ASD with Tuberous Sclerosis as a Model (PDF – 1 MB	Mustafa Sahin, M.D., Ph.D., Director of Translational Neuroscience Center, Boston, Children's Hospital, Associate Professor of Neurology, Harvard Medical School, Harvard University
Immune System and Autism Spectrum Disorders (PDF – 6 MB)	Carlos Pardo-Villamizar, M.D., Associate Professor of Neurology and Pathology, School of Medicine, Johns Hopkins University; Judy Van de Water, Ph.D., Professor, Department of Internal Medicine, School of Medicine, Director, Center for Children's Environmental Health, Co-Director, Intellectual and Developmental Disabilities Research Center (IDDRC), MIND Institute, University of California, Davis
Emerging Patterns of Metabolic Disturbance in Autism Spectrum Disorders (PDF – 6 MB)	Robert K. Naviaux, M.D., Ph.D., M.S., Professor, Departments of Medicine, Pediatrics, and Pathology, Co-Director, Mitochondrial and Metabolic Disease Center, Director of Metabolomics Core, Veterans Affairs, Center for Excellence in Stress and Mental Health, School of Medicine, University of California, San Diego

Back to Top

• Meeting Transcript (PDF – 2 MB)

Back to Top